Your browser is no longer supported. Please, upgrade your browser.
Settings
JNJ Johnson & Johnson daily Stock Chart
JNJ [NYSE]
Johnson & Johnson
IndexDJIA S&P500 P/E22.11 EPS (ttm)5.49 Insider Own0.02% Shs Outstand2.75B Perf Week4.89%
Market Cap333.63B Forward P/E17.32 EPS next Y7.00 Insider Trans-23.40% Shs Float2.75B Perf Month5.94%
Income15.38B PEG3.69 EPS next Q1.69 Inst Own67.00% Short Float0.92% Perf Quarter12.49%
Sales70.18B P/S4.75 EPS this Y-3.90% Inst Trans-0.67% Short Ratio3.48 Perf Half Y19.78%
Book/sh26.35 P/B4.60 EPS next Y6.01% ROA11.50% Target Price117.89 Perf Year26.88%
Cash/sh14.49 P/C8.37 EPS next 5Y6.00% ROE21.50% 52W Range80.04 - 121.41 Perf YTD19.78%
Dividend3.20 P/FCF52.83 EPS past 5Y2.80% ROI16.90% 52W High-0.10% Beta0.57
Dividend %2.64% Quick Ratio2.50 Sales past 5Y2.60% Gross Margin69.30% 52W Low51.54% ATR1.32
Employees127100 Current Ratio2.80 Sales Q/Q0.60% Oper. Margin27.00% RSI (14)73.53 Volatility1.32% 1.05%
OptionableYes Debt/Eq0.32 EPS Q/Q0.40% Profit Margin21.90% Rel Volume0.97 Prev Close121.30
ShortableYes LT Debt/Eq0.28 EarningsJul 19 BMO Payout53.90% Avg Volume7.24M Price121.29
Recom2.40 SMA203.84% SMA506.11% SMA20016.56% Volume7,050,857 Change-0.01%
May-20-16Initiated Standpoint Research Sell $94
Apr-20-16Reiterated RBC Capital Mkts Outperform $122 → $125
Apr-20-16Reiterated Piper Jaffray Neutral $105 → $106
Apr-15-16Reiterated RBC Capital Mkts Outperform $114 → $122
Mar-14-16Upgrade Goldman Sell → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $101 → $115
Oct-05-15Resumed Piper Jaffray Neutral $105
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Dec-16-13Reiterated Deutsche Bank Hold $93 → $95
Jul-18-13Reiterated Argus Buy $96 → $104
Jul-17-13Reiterated Barclays Overweight $95 → $99
Jul-17-13Downgrade Deutsche Bank Buy → Hold $92 → $93
Apr-18-13Reiterated Argus Buy $80 → $96
Apr-15-13Reiterated Barclays Overweight $85 → $95
Jul-01-16 06:19PM  J&J's Janssen hit with $70 mln verdict in Risperdal trial Reuters
05:07PM  J&J Hit With $70 Million Risperdal Verdict Over Male Breasts at Bloomberg
04:46PM  Week ahead: The stock market roller coaster won't stop at CNBC
04:30PM  Shire Stock Up Despite Mixed Data on Pipeline Candidate
04:00PM  Johnson & Johnson Targets 85% of Apps in Cloud by 2018 at The Wall Street Journal
03:51PM  J&J's Janssen hit with $70 mln verdict in Risperdal trial -lawyers
02:40PM  This $6.7 Billion Drug Just Keeps Growing at Motley Fool
11:07AM  What Are the Benefits of the Novartis-Xencor Alliance to Xencor?
10:17AM  Johnson & Johnson Headed Higher & Higher
09:30AM  Owens-Illinois, Korn Ferry, AbbVie and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
Jun-30-16 06:31PM  Tesaro Stock Up on Successful Phase III Ovarian Cancer Trial
06:28PM  McKesson Raises View Due to Accounting Changes, Stock Up
03:54PM  What Is Xencors XmAb Technology?
02:20PM  Is Pfizers Valuation Low Compared to Peers?
01:30PM  This 5-Stock Portfolio Makes the Perfect Summer Gift at Kiplinger
09:38AM  AbbVie, J&J's Imbruvica Gets Breakthrough Therapy Status
09:29AM  Q3: BEST CHANCE FOR RETURNS THIS YEAR?
08:44AM  5 Defensive Stocks to Buy in 2016 at Motley Fool
Jun-29-16 02:29PM  The Market Value Fluctuations of the 10 Largest Companies
12:28PM  How J&J Defied Brexit and Became the Year's Top Health Care Stock
10:41AM  2 Reasons Behind Johnson & Johnson's 15% Year-to-Date Share-Price Increase at Motley Fool
09:33AM  [$$] Tesaro's Cancer Drug Meets Primary Endpoint in Late-Stage Trial at The Wall Street Journal
09:30AM  Zacks Market Edge Highlights: Johnson & Johnson, Priceline, Target, Tesla and Alphabet
09:18AM  Brexit Bargains To Buy Now at Forbes
09:00AM  Research Report Initiated on Select Major Drug Manufacturers Equities
Jun-28-16 08:23PM  How to Trade Earnings Season
07:01PM  Cramer: The 3 Stocks That Will Tell You If the Rally Is Real
05:16PM  Stocks surviving the Brexit
03:57PM  Online networks create programming for the digitally minded mom at CNBC
01:36PM  There are reasons not to get too happy about this stock rally at CNBC
12:10PM  5 Companies Hit 52-Week Highs
10:03AM  5 Medical Stocks to Buy with Great Dividend Yields
Jun-27-16 08:32PM  Forget Financials, Buy These Consumer Staples Stocks Instead
08:17PM  Jim Cramer's 'Mad Money' Recap: 'Brexit' Is the Dumbest Financial Mistake Ever
07:32PM  Cramer's Brexit shopping list
07:01PM  Cramer: There's a Lot Out There That's Tempting
04:38PM  Dow, S&P Breach Key Support; UK Credit Ratings Cut As Brexit Fallout Continues
04:01PM  JP Morgan: Dividend Payers Are Best Post-Brexit Stock Option at Barrons.com
03:30PM  ETFs with exposure to Johnson & Johnson : June 27, 2016
01:51PM  Stock Indexes Take Hard Shots, But These 3 Dow Components Hold Up at Investor's Business Daily
11:01AM  50 Stocks to Brighten the Post-Brexit Blues at Barrons.com
09:41AM  The One Stock to Immunize Your Portfolio From the Brexit Contagion
08:14AM  10 Best Post-Brexit Stocks to Buy at a Discount Now
Jun-25-16 12:05PM  How Did Roches Diagnostics Division Perform?
11:00AM  3 Small-Cap Stocks to Buy in July at Motley Fool
08:28AM  3 Stocks with Better Dividends Than Procter & Gamble Co. at Motley Fool
Jun-24-16 08:20PM  3 Stocks to Help You Build Retirement Wealth at Motley Fool
02:09PM  New Stock Research Reports for June 24, 2016
01:38PM  How Has Becton Dickinsons Stock Performed?
12:17PM  Genmab/Novartis' Arzerra Gets Unfavorable CHMP Opinion
10:20AM  Johnson & Johnson :JNJ-US: Earnings Analysis: Q1, 2016 By the Numbers : June 24, 2016
10:08AM  Gilead's (GILD) HIV Treatment Odefsey Gains Approval in EU
07:00AM  There's Value in This High-Dividend ETF at Morningstar
Jun-23-16 11:30AM  Gilead Sciences Get European Commission Grant For Marketing Authorization Of Its Single Tablet Regimen Odefsey
10:41AM  The 3 Most Important Data Releases and FDA Decisions in the Second Half of 2016 at Motley Fool
Jun-22-16 07:37PM  A Secure 4% 'No Withdrawal' Retirement Portfolio at Forbes
02:22PM  SunPower's CEO Werner: 'Grid Parity Is Happening as We Speak' at Barrons.com
02:12PM  Technology Forces Advertisers To Get Creative
01:00PM  IBM Watson Imaging Collaborative Adds 16 Health Systems, Tech Firms at Forbes
09:07AM  Zimmer Biomet to Strengthen its Spine Business through LDR Acquisition
08:21AM  Can These Upstarts Knock Gilead Sciences Off Its Perch? at Motley Fool
07:24AM  Johnson & Johnson Names Joseph Wolk As VP Of Investor Relations In Place Of Louise Mehrotra
06:45AM  Johnson & Johnson Announces Retirement of Louise Mehrotra and Appointment of Joseph Wolk as Vice President of Investor Relations PR Newswire
Jun-21-16 03:52PM  7 Profitable Medical Stocks Ranked as Buys Now
02:49PM  Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results PR Newswire
02:02PM  Countdown to Brexit
01:20PM  $586M deal: Impax buying generic drugs FTC asked Teva and Allergan to sell at bizjournals.com
12:01PM  3 Attractive Income Stocks Whose Dividends Could Double at Motley Fool
09:30AM  Commercial Vehicle Group, Houlihan Lokey, Johnson & Johnson and Canadian Imperial Bank of Commerce highlighted as Zacks Bull and Bear of the Day
12:11AM  [$$] Carlyle Group Hires Former J&J Executive to Advise Asia Buyout Fund at The Wall Street Journal
Jun-20-16 07:08PM  [$$] Carlyle Group Hires Former J&J Exec to Advise Asia Buyout Fund at The Wall Street Journal
06:04PM  Why Achillion Pharmaceuticals Is Down Big in 2016 at Motley Fool
02:02PM  Top Stock PIcks for the Week of June 20th
01:01PM  This New Class Of Medicine Could Reshape Diabetes Treatment at Motley Fool
01:00PM  Volatility Ramps Up and Spreads Reverse Course
10:03AM  3 Safe Stocks You Can Buy Right Now at Motley Fool
09:07AM  Jefferies Rated Procter & Gamble as a Buy
Jun-19-16 06:06PM  Better Buy: AbbVie Inc. vs. Johnson & Johnson at Motley Fool
02:03PM  1 Stock to Invest in Big Pharma at Motley Fool
Jun-18-16 12:01PM  Forget TransEnterix Inc: This is The Company That Intuitive Surgical Investors Should Fear Most at Motley Fool
11:00AM  Top 2 Holdings of Columbia Threadneedle's Mutual Fund (MSFT, JNJ) at Investopedia
09:03AM  Diabetes Deep-Dive: What Investors Need to Know About This Devastating Disease at Motley Fool
04:24AM  Tech Women Triumph: The Change Is Happening At Facebook, Johnson & Johnson, eBay And GM at Forbes
Jun-17-16 03:04PM  Get Higher Returns and More Dividend Income a In Less Time With Less Risk
08:37AM  Here's the game plan for dealing with the Fed, Brexit and oil
07:42AM  9 Easy Ways to Lose Money in the Stock Market at Motley Fool
07:00AM  Is No Oil Company is Safe?
12:23AM  Aegerion, QLT Ink Merger Deal to Form Novelion Therapeutics
Jun-16-16 08:33PM  Jim Cramer's 'Mad Money' Recap: An Epic Battle of 'Brexit' vs. Oil
06:33PM  Why This Pharma Giant Lost $8 Billion in Market Cap This Week at Fortune
Jun-15-16 05:19PM  Shire Buys Global Rights to Pfizer's Gastrointestinal Drug
12:23PM  Better Buy: Johnson & Johnson vs. Eli Lilly at Motley Fool
Jun-14-16 07:00PM  Opportunities and Pitfalls for Bottom-Up Stock-Pickers at Morningstar
04:07PM  Johnson & Johnson (JNJ) Stock Price Target Raised at Jefferies
03:07PM  1 Stock to Invest in Healthcare at Motley Fool
12:43PM  a5 Years With Johnson & Johnson
Jun-13-16 02:47PM  Microsoft's Triple-A credit under review at Moody's after LinkedIn acquisition at MarketWatch
02:33PM  Moody's reviews Microsoft credit rating for cut after LinkedIn deal Reuters
10:25AM  Johnson & Johnson recruits top Zika researcher to Houston at bizjournals.com
Jun-11-16 01:40PM  J&J preparing to launch a new mealtime insulin delivery patch at bizjournals.com
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women's health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages under the BAND-AID brand name and first aid products under the NEOSPORIN brand name. This segment also provides over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company offers its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kapusta Ronald AController, CAOJun 07Option Exercise58.333,000174,99028,725Jun 09 04:11 PM
Pruden Gary JExec VP, WW Chair, Med DevicesJun 07Sale116.039,7351,129,55243,630Jun 09 04:12 PM
Kapusta Ronald AController, CAOJun 07Sale115.793,000347,38125,725Jun 09 04:11 PM
Kapusta Ronald AController, CAOMay 10Option Exercise58.333,957230,81229,682May 12 05:09 PM
Kapusta Ronald AController, CAOMay 10Sale114.773,957454,15725,725May 12 05:09 PM
Caruso Dominic JVP, Finance; CFOFeb 08Option Exercise0.0029,0050125,466Feb 10 06:02 PM
Gorsky AlexChairman, CEOFeb 08Option Exercise0.0067,9330197,441Feb 10 06:02 PM
PETERSON SANDRA EGroup Worldwide ChairmanFeb 08Option Exercise0.007,633037,943Feb 10 06:03 PM
Fasolo PeterVP, Global Human ResourcesFeb 08Option Exercise0.0018,777056,512Feb 10 06:03 PM
Ullmann Michael HVP, General CounselFeb 08Option Exercise0.0016,697098,071Feb 10 06:03 PM
Stoffels PaulusChief Scientific OfficerFeb 08Option Exercise0.0028,2420131,104Feb 10 06:03 PM
Kapusta Ronald AController, CAOFeb 08Option Exercise0.002,598026,023Feb 10 06:03 PM
Fasolo PeterVP, Global Human ResourcesFeb 03Option Exercise72.54144,56810,486,963182,303Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 03Sale104.12144,56815,052,42037,735Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 02Option Exercise72.546,817494,50544,552Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 02Sale104.096,817709,58837,735Feb 04 06:04 PM
Caruso Dominic JVP, Finance; CFOJan 15Option Exercise0.0011,6020100,336Jan 20 07:25 PM
Fasolo PeterVP, Global Human ResourcesJan 15Option Exercise0.007,511040,578Jan 20 07:25 PM
Gorsky AlexChairman, CEOJan 15Option Exercise0.0027,1730140,534Jan 20 07:25 PM
PETERSON SANDRA EGroup Worldwide ChairmanJan 15Option Exercise0.003,053031,616Jan 20 07:25 PM
Ullmann Michael HVP, General CounselJan 15Option Exercise0.006,679083,907Jan 20 07:25 PM
Kapusta Ronald AController, CAOJan 15Option Exercise0.003,896024,699Jan 20 07:25 PM
Stoffels PaulusChief Scientific OfficerJan 15Option Exercise0.0011,2970106,585Jan 20 07:25 PM
PETERSON SANDRA EGroup Worldwide ChairmanDec 17Option Exercise0.0021,688040,730Dec 21 05:09 PM
Ullmann Michael HVP, General CounselNov 20Option Exercise58.3422,6261,320,00194,878Nov 24 01:00 PM
Ullmann Michael HVP, General CounselNov 20Sale102.4717,6501,808,54377,228Nov 24 01:00 PM
Caruso Dominic JVP, Finance; CFONov 02Option Exercise58.3420,5691,199,995109,303Nov 04 05:05 PM
Caruso Dominic JVP, Finance; CFONov 02Sale102.2120,5692,102,42388,734Nov 04 05:05 PM
Kapusta Ronald AController, CAOOct 23Option Exercise58.346,239363,98327,042Oct 27 03:38 PM
Kapusta Ronald AController, CAOOct 23Sale99.686,239621,90420,803Oct 27 03:38 PM
PRINCE CHARLESDirectorAug 06Buy99.252,500248,13225,645Aug 10 12:49 PM